PONTE VEDRA BEACH, Fla., June 7, 2021 – RedDress, a privately held U.S. and Israel-based wound care company, announced today that its product, ActiGraft®, has been added to Marathon Medical’s contract with the Federal Supply Schedule (FSS).

 

This contract allows RedDress to partner with Marathon Medical to make ActiGraft available at veteran health facilities and other federal health facilities around the country. The VA system is the largest integrated health care system in the United States with over 1,300 facilities. These facilities include VA Medical Centers, Outpatient Clinics, Community Based Outpatient Clinics and VA Community Living Centers.

 

“We are thrilled to have secured this contract and begin a partnership with Marathon Medical and the Department of Veteran Affairs. This alliance ensures that veterans, active soldiers, and patients across the VA health system have access to ActiGraft to help treat their cutaneous wounds,” said ­­­­­­Robert Mueller, General Manager of RedDress.

 

ActiGraft is the first wound care product that enables health care providers to produce—in real time— in vitro blood clot tissue from a patient’s own blood. Once applied, the blood clot tissue serves as a protective covering and supports the body’s natural wound healing response. ActiGraft can be used for a wide variety of hard-to-treat chronic wounds, including diabetic foot ulcers, pressure injuries, venous ulcers, traumatic wounds, post-surgical wounds, skin tears.

 

“It is estimated that chronic wounds impact nearly 7 million people in the U.S., many of which are Veterans,” said Alon Kushnir, CEO of RedDress. “Our partnership with Marathon Medical and the inclusion of ActiGraft on the FSS enables us to further our commitment to helping the wounded by providing access to an effective, comfortable, and affordable product.”

 

RedDress was awarded contract number # 36F79718D0321 in early 2021.

 

 

About ActiGraft®

ActiGraft, based on RedDress’ proprietary patented technology, is an FDA-cleared wound care solution that enables health care providers to produce – in real time – in vitro blood clot tissue from a patient’s whole blood. Once applied, the blood clot tissue serves as a protective covering and supports wound healing processes which naturally occur in the patient’s body.

 

ActiGraft is intended for exuding cutaneous wounds. ActiGraft is intended for exuding cutaneous wound types. The ActiGraft Kit includes blood-contacting components that have been sterilized by Ethylene Oxide, which may cause serious allergic reactions in patients that are sensitized. For full prescribing information, visit www.reddressmedical.com/safety-info.

 

 

About RedDress®

RedDress (www.reddressmedical.com) is a privately held, Israel-based company with a U.S. subsidiary, RedDress Inc., located in Ponte Vedra Beach, Florida. Founded in 2009 with the goal of developing more effective, natural, and economically viable treatments for chronic wounds, RedDress is committed to improving the health and lives of patients around the world with its latest innovation – ActiGraft.

 

 

Press & Media Inquiries

Alessandra Lalli, RedDress

alalli@reddressmedical.com

 

Investor Inquiries

Russell Lalli, RedDress

rlalli@reddressmedical.com

crossmenu